We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Presents Positive Early Data from Alzheimer's Study
Read MoreHide Full Article
Last week, Biogen Inc. (BIIB - Free Report) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
Biogen’s share price has slipped 10.5% in the past one month, underperforming a decrease of 6.7% witnessed by the Zacks classified Biomed/Genetics industry.
Coming back to the latest news, PRIME, a randomized, double-blind, placebo-controlled, multiple-dose phase Ib study, is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of aducanumab in patients suffering from prodromal or mild AD.
Data presented included interim results from the titration cohort of the placebo-controlled period of the PRIME study as well as data from the first year of the long-term extension (LTE).
Data from the titration cohort revealed that when treated with aducanumab, patients experienced a statistically significant reduction in amyloid plaque in the brain after 54 weeks of treatment in all fixed-dose arms (1, 3, 6 or 10 mg/kg arms). In the LTE, there were no new cases of amyloid-related imaging abnormalities in patients initially randomized to aducanumab 3, 6 or 10 mg/kg, who were treated up to 24 months.
Last month, Eli Lilly and Company (LLY - Free Report) announced that its high-profile investigational Alzheimer’s disease drug, solanezumab, has failed to meet the primary endpoint in a late-stage study. With the failure, Lilly decided to cease the development of solanezumab. Shares of Lilly tanked on the news, casting uncertainties over other Alzheimer’s programs like aducanumab that were based on the beta amyloid hypothesis (Read: Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?). Note that beta amyloid, a protein that forms plaques in the brain, plays an important role in Alzheimer's disease.
Biogen’s latest results have rekindled hopes that beta amyloid targeting antibodies may offer an effective treatment for Alzheimer's disease.
Currently, Biogen is conducting two other phase III studies (ENGAGE and EMERGE) on aducanumab for the treatment of early AD.
Last week Lilly and AstraZeneca plc (AZN - Free Report) announced that were expanded their existing collaboration to develop their second treatment for Alzheimer's disease, MEDI1814. MEDI1814, which is in phase I studies, is also an antibody targeting beta amyloid.
Another company that is developing antibody treatments targeting beta amyloid is Roche Holding AG (RHHBY - Free Report) .
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen Presents Positive Early Data from Alzheimer's Study
Last week, Biogen Inc. (BIIB - Free Report) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
Biogen’s share price has slipped 10.5% in the past one month, underperforming a decrease of 6.7% witnessed by the Zacks classified Biomed/Genetics industry.
Coming back to the latest news, PRIME, a randomized, double-blind, placebo-controlled, multiple-dose phase Ib study, is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of aducanumab in patients suffering from prodromal or mild AD.
Data presented included interim results from the titration cohort of the placebo-controlled period of the PRIME study as well as data from the first year of the long-term extension (LTE).
Data from the titration cohort revealed that when treated with aducanumab, patients experienced a statistically significant reduction in amyloid plaque in the brain after 54 weeks of treatment in all fixed-dose arms (1, 3, 6 or 10 mg/kg arms). In the LTE, there were no new cases of amyloid-related imaging abnormalities in patients initially randomized to aducanumab 3, 6 or 10 mg/kg, who were treated up to 24 months.
Last month, Eli Lilly and Company (LLY - Free Report) announced that its high-profile investigational Alzheimer’s disease drug, solanezumab, has failed to meet the primary endpoint in a late-stage study. With the failure, Lilly decided to cease the development of solanezumab. Shares of Lilly tanked on the news, casting uncertainties over other Alzheimer’s programs like aducanumab that were based on the beta amyloid hypothesis (Read: Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?). Note that beta amyloid, a protein that forms plaques in the brain, plays an important role in Alzheimer's disease.
Biogen’s latest results have rekindled hopes that beta amyloid targeting antibodies may offer an effective treatment for Alzheimer's disease.
Currently, Biogen is conducting two other phase III studies (ENGAGE and EMERGE) on aducanumab for the treatment of early AD.
Last week Lilly and AstraZeneca plc (AZN - Free Report) announced that were expanded their existing collaboration to develop their second treatment for Alzheimer's disease, MEDI1814. MEDI1814, which is in phase I studies, is also an antibody targeting beta amyloid.
Another company that is developing antibody treatments targeting beta amyloid is Roche Holding AG (RHHBY - Free Report) .
Biogen carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>